These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 19275492

  • 1. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.
    Clin Infect Dis; 2009 Apr 15; 48(8):1152-9. PubMed ID: 19275492
    [Abstract] [Full Text] [Related]

  • 2. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, AIDS Clinical Trials Group A5071 Study Team.
    N Engl J Med; 2004 Jul 29; 351(5):451-9. PubMed ID: 15282352
    [Abstract] [Full Text] [Related]

  • 3. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group.
    N Engl J Med; 2004 Jul 29; 351(5):438-50. PubMed ID: 15282351
    [Abstract] [Full Text] [Related]

  • 4. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 5. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team.
    JAMA; 2004 Dec 15; 292(23):2839-48. PubMed ID: 15598915
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI.
    J Antimicrob Chemother; 2008 Oct 15; 62(4):793-6. PubMed ID: 18567911
    [Abstract] [Full Text] [Related]

  • 7. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T.
    Gastroenterology; 2011 Nov 15; 141(5):1656-64. PubMed ID: 21784046
    [Abstract] [Full Text] [Related]

  • 8. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1839-50. PubMed ID: 19403903
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    Craxi A, Koutsounas S, Ogurtsov P, Chemello L, Maticic M, Torras J, Diago M, Tartaglione MT, Witthoeft T, Yu X, Faruqi R, Chaudhri E, Pedicone LD, Zuckerman E.
    J Viral Hepat; 2012 Feb 30; 19(2):e120-5. PubMed ID: 22239509
    [Abstract] [Full Text] [Related]

  • 10. A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
    Rivero-Juarez A, López-Cortés LF, Camacho A, Mira JA, Téllez F, Marquez M, Merino D, Pineda JA, Rivero A, Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR), part of the Sociedad Andaluza de Enfermedades Infecciosas.
    Clin Infect Dis; 2014 Jan 30; 58(1):130-3. PubMed ID: 24065317
    [Abstract] [Full Text] [Related]

  • 11. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H, Laskus T, Kołakowska-Rządzka A, Wasilewski M, Stańczak JJ, Bardadin K, Walewska-Zielecka B, Horban A.
    Adv Med Sci; 2014 Sep 30; 59(2):261-5. PubMed ID: 25117425
    [Abstract] [Full Text] [Related]

  • 12. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1827-38. PubMed ID: 19403902
    [Abstract] [Full Text] [Related]

  • 13. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, Esteban R, Guardia J, Ocaña I, Pahissa A.
    AIDS; 2007 Feb 19; 21(4):477-81. PubMed ID: 17301566
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B, CORAL-1 study group.
    J Viral Hepat; 2007 Oct 19; 14(10):704-13. PubMed ID: 17875005
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.
    J Viral Hepat; 2007 Oct 19; 14(10):721-9. PubMed ID: 17875007
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T, Nonresponder Retreatment Group.
    Gastroenterology; 2006 Apr 19; 130(4):1098-106. PubMed ID: 16618404
    [Abstract] [Full Text] [Related]

  • 19. Telaprevir for retreatment of HCV infection.
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2417-28. PubMed ID: 21696308
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J.
    J Hepatol; 2006 Jan 23; 44(1):97-103. PubMed ID: 16290907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.